Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CUE-101

Fusion protein · Immune activation, directed at HPV16 E7 protein (residues 11-20 epitope) · developed by Cue Biopharma

Phase 2 Most advanced trial
CUE Developer
1 Registered trials

What is CUE-101?

CUE-101 is a fusion protein combining an HLA-A*0201 complex loaded with an HPV16 E7 peptide epitope, a reduced-affinity interleukin-2 variant, and an attenuated IgG1 Fc domain. It binds E7-specific CD8-positive T cells, promoting their activation, expansion and interferon gamma secretion. It is being studied in oropharyngeal squamous cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Fusion protein
Targets
HPV16 E7 protein (residues 11-20 epitope) (antigen)
Mechanism
Immune activation, directed at HPV16 E7 protein (residues 11-20 epitope)
Pathways
T-cell activation and expansion, IFN gamma cytokine secretion
Therapy area
Oncology
Developer
Cue Biopharma (CUE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07172256 Phase 2 Head and Neck Squamous Cell Carcinoma Recruiting CUE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Oropharyngeal Squamous Cell Carcinoma

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the CUE page.

Follow CUE, the company behind CUE-101

See CUE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CUE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.